Processa Pharmaceuticals Inc
PCSA
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.76M
Close$
$4.23
94% upside
Current Fair Value
94% upsideUndervalued by 94% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.76 Million |
|---|---|
| Enterprise Value | $5.56 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-10.36 |
| Beta | 0.96 |
| Outstanding Shares | 2,750,742 |
Return
| Return on Equity | 4234.62% |
|---|---|
| Return on Assets | -649.33% |
| Return on Invested Capital | -3225.03% |
Valuation & Multiples
| P/E Ratio | -0.37 |
|---|---|
| PEG | 2.19 |
| Price to Sales | - |
| Price to Book Ratio | -2.18 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.54 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-1.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Processa Pharmaceuticals Inc
14 employeesProcessa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Company acquired the as...